CD184 (CXCR4) receptor was upregulated in moderate brain injury and downregulated in the severe type, highlighting that CPCs’ mobilization through the SDF-1/CXCR4 axis is indeed intense in moderate encephalopathy (the 8-fold increase in CD184+ cells on day 9 observed in this group is noteworthy) and malfunctions in severe brain injury. This evidence concerns the gene CXCL12 and Encephalopathy.